Laboratory of Drug Metabolism and Pharmacokinetics, Showa Pharmaceutical University, Machida, Tokyo, 194-8543, Japan.
Central Institute for Experimental Animals, Kawasaki, 210-0821, Japan.
Drug Metab Pharmacokinet. 2021 Apr;37:100369. doi: 10.1016/j.dmpk.2020.11.004. Epub 2020 Nov 13.
Flavin-containing monooxygenase (FMO) catalyzes the oxygenation of a wide variety of medicines and dietary-derived compounds. However, little information is available regarding drug interactions mediated by FMO3 in vivo. Consequently, we investigated interactions between FMO substrates in humanized-liver mice. Trimethylamine-d and itopride were, respectively, intravenously and orally administered to humanized-liver mice (n = 5-7). The pharmacokinetic profiles of itopride (the victim drug) in the presence of trimethylamine (the perpetrator drug) were determined for 24 h after co-administration using liquid chromatography/tandem mass spectrometry. Itopride (10 mg/kg) was extensively oxygenated in humanized-liver mice to its N-oxide. The plasma concentrations of itopride N-oxide after co-administration of itopride and trimethylamine (10 and 100 mg/kg) were significantly suppressed in a dose-dependent manner, but only during the early phase, i.e., up to 2 h after co-administration. With the higher dose of trimethylamine, the areas under the concentration-time curves of itopride and its N-oxide significantly increased (1.6-fold) and decreased (to 60%), respectively; modeling suggested that these modified pharmacokinetics resulted from suppression of the in vivo hepatic intrinsic clearance (to 67%). These results suggest that food-derived trimethylamine may result in interactions with FMO drug substrates immediately after administration; however, the potential for this to occur in vivo may be limited.
黄素单加氧酶(FMO)催化多种药物和膳食来源化合物的氧化。然而,关于 FMO3 在体内介导的药物相互作用的信息很少。因此,我们在人源化肝脏小鼠中研究了 FMO 底物之间的相互作用。分别静脉内和口服给予三甲胺-d 和伊托必利于人源化肝脏小鼠(n=5-7)。在共同给予后 24 小时内使用液相色谱/串联质谱法确定存在三甲胺(加害人药物)时伊托必利(受药物)的药代动力学特征。伊托必利(10mg/kg)在人源化肝脏小鼠中被广泛氧化为其 N-氧化物。共同给予伊托必利和三甲胺(10 和 100mg/kg)后,伊托必利 N-氧化物的血浆浓度呈剂量依赖性显著抑制,但仅在早期,即在共同给予后 2 小时内。使用较高剂量的三甲胺,伊托必利及其 N-氧化物的浓度-时间曲线下面积分别显著增加(1.6 倍)和减少(至 60%);模型表明这些改变的药代动力学是由于体内肝内在清除率的抑制(至 67%)所致。这些结果表明,食物来源的三甲胺可能会在给药后立即与 FMO 药物底物发生相互作用;然而,这种相互作用在体内发生的可能性可能有限。